Mohammed A Nayeem
Department of Pharmaceutical Sciences, School of Pharmacy, Center for Basic and Translational Stroke Research
West Virginia University, USA
Mohammed A. Nayeem, MSc, PhD., Department of Pharmaceutical Sciences, School of Pharmacy, WVU. Dr. Nayeem has research interest in understanding the role of epoxygenases, soluble epoxide hydrolase, ω-hydroxylases, arachidonic acids-derived oxylipins and PPARγ in transgenic mouse models for hypertension, salt-sensitive hypertension and coronary hyperemic response, and their therapeutic targets.
My research is really focused on the role of adenosine A2A receptors, PPARα, PPARγ, CYP450-epoxygenases (CYP2C, CYP2J2, CYP2J5), soluble epoxide hydrolase, ω-hydroxylases and oxylipins profile (5,6-, 8,9-, 11,12- and 14,15-EET, 5,6-, 8,9-, 11,12- and 14,15-DHET, 5-, 8-, 9-, 11-, 12- and 15-HETE, 9,10- and 12,13-EpOME, 9,10- and 12,13-DiHOME, 9- and 13-HODE, 6-keto prostaglandin-F1α [6K-PG-F1α], PG-F2α, thromboxane B2 [TxB2], PGD2, and PGE2) in the modulation of vascular response including coronary circulation (hyperemic response), and leading to change in the blood pressure (essential hypertension/salt-sensitive hypertension). We use pharmacology and gene manipulated technology in mouse models, because genetic polymorphism has been seen in human population which may cause essential hypertension/salt sensitive hypertension and blunting of hyperemic response. I believe the identification of the signaling pathway or pathways will help to unravel the potential mechanisms involve A2A AR, PPARγ, CYP2J2, sEH, CYP4A and Oxylipins in the vascular regulation of hypertension and coronary reactive hyperemia.
